Osagie Ebekozien, United States of America
T1D Exchange Quality IMprovement and Population HealthPresenter of 1 Presentation
ACUTE CLINICAL OUTCOMES IN COVID-19 POSITIVE PATIENTS WITH TYPE 1 DIABETES (T1D) USING INSULIN PUMP FOR DIABETES MANAGEMENT: DATA FROM THE T1D EXCHANGE COVID REGISTRY
- Osagie Ebekozien, United States of America
- Anastasia Albanese, United States of America
- Nudrat Noor, United States of America
- Zoltan Antal, United States of America
- Paul Thornton, United States of America
- Robert Rapaport, United States of America
- Mary Pat Gallagher, United States of America
- Laura Levin, United States of America
Abstract
Background and Aims
The use of continuous subcutaneous insulin infusion (CSII) has demonstrated fewer acute complications in patients with type 1 diabetes (T1D). This study aims to examine the frequency of adverse clinical outcomes among T1D patients who tested positive for COVID-19 and were users versus non-users of insulin pump therapy.
Methods
The analysis included 241 T1D patients from the T1DX-QI COVID-19 registry who tested positive for COVID-19. Healthcare providers extracted patient data from electronic medical records of 52 endocrinology clinics across the U.S. Data was collected from April 2020 to September 2020.
Results
In this population, 38% (N=92) of T1D patients were insulin pump users, whereas 62% (N=149) were non-users. HbA1c levels in the insulin pump group were lower compared to non-users (Median [IQR], %: 8.0 [1.9] vs. 9.8 [3.7] [p<0.001]). Adverse events, such as diabetic ketoacidosis, were less frequently recorded for insulin pump users relative to the non-users (9% vs.30%) [p<0.001]. Further, patients who did not use insulin pump therapy were more likely to be hospitalized (29% vs.12%) [p<0.001] or need ICU care [25% vs.4%) [p<0.001] than patients who used insulin pumps.
Conclusions
Patients with established T1D and COVID-19 who used insulin pump therapy for diabetes management had lower rates of adverse clinical outcomes.